ArticleNature communications2025
Characterizing trachoma elimination using serology.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Impact of two rounds of azithromycin mass drug administration on active trachoma and ocular Chlamydia trachomatis infection in Naoero.PLoS neglected tropical diseases · 2026Article
- Reconstruction of historical malaria transmission in Senegal using multiplex serocatalytic models.PLoS computational biology · 2026Article
- Multi-pathogen serosurveillance in Tonga examining demographic correlates and geographic clustering of 17 pathogens.Scientific reports · 2026Article
- National progress towards the elimination of trachomatous inflammation-follicular: analysis of 11 regions in Ethiopia.International health · 2026Article
- Does persistent active trachoma mandate antibiotic mass drug administration? A comparison of prevalence of trachomatous inflammation-follicular with that of conjunctival infection and anti-chlamydial antibodies, Western Province, Zambia.International health · 2026Article
- Integrated serosurveillance to assess disease elimination in coastal Ecuador: onchocerciasis, yaws, and trachoma.medRxiv : the preprint server for health sciences · 2026Article
- Monitoring of Chlamydia trachomatis infection and antibodies in low-prevalence districts of Amhara, Ethiopia: Insights from a hyper-endemic trachoma region.PLoS neglected tropical diseases · 2026Article
- Integrated serosurveillance of multiple communicable diseases in the hinterland of Guyana.Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Impact of evidence-based programmatic adaptations in addressing the persistence and recrudescence of trachoma in Kajiado County, Kenya.International health · 2025Article
- Data Resource Profile: Global Trachoma Serology Data Repository.International journal of epidemiology · 2025Article
- serocalculator, an R package for estimating seroincidence from cross-sectional serological data.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
- Update of
Authors and funding
68 authors.
Everlyn KamauF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA. everlyn.kamau@ucsf.edu.ORCID http://orcid.org/0000-0003-4285-2255
Pearl Anne Ante-TestardF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3416-0817
Sarah GwynDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-1856-3165
Seth BlumbergF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5495-4238
Zeinab AbdallaThe Carter Center, Khartoum, Sudan.
Kristen AiemjoyDepartment of Public Health Sciences, School of Medicine, University of California Davis CA, Davis, CA, USA.ORCID http://orcid.org/0000-0003-1886-2699
Abdou AmzaProgramme National de Lutte Contre la Cecité, Niamey, Niger.
Solomon AragieF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Ahmed M ArzikaCentre de Recherche et d'interventions en Sante Publique, CRISP, Niamey, Niger.
Marcel S AwoussiMinistère de la Santé et de L'Hygiène Publique, Lomé, Togo.
Robin L BaileyLondon School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0002-8770-1680
Robert ButcherLondon School of Hygiene & Tropical Medicine, London, UK.
E Kelly CallahanThe Carter Center, Atlanta, GA, USA.
David ChaimaKamuzu University of Health Sciences, Lilongwe, Malawi.
Adisu Abebe DawedAmhara Regional Health Bureau, Bahir Dar, Ethiopia.
Martha Idalí Saboyá DíazDepartment of Prevention, Control, and Elimination of Communicable Diseases, Pan American Health Organization, Washington, DC, USA.ORCID http://orcid.org/0000-0003-4324-9618
Abou-Bakr Sidik DomingoMinistère de la Santé et de L'Hygiène Publique, Lomé, Togo.
Chris DrakeleyLondon School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0003-4863-075X
Belgesa E ElshafieMinistry of Health, Khartoum, Sudan.
Paul M EmersonInternational Trachoma Initiative, Atlanta, GA, USA.
Kimberly FornaceSaw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Katherine GassNeglected Tropical Diseases Support Center, Task Force for Global Health, Atlanta, GA, USA.
E Brook GoodhewDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jaouad HammouDirection de l'Epidemiologie et de Lutte contre les Maladies, Rabat, Morocco.
Emma M Harding-EschLondon School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0002-1432-8109
P J HooperInternational Trachoma Initiative, Atlanta, GA, USA.
Boubacar KadriThe Carter Center, Khartoum, Sudan.
Khumbo KaluaUniversity of British Columbia, Vancouver, Canada.
Sarjo KanyiThe National Eye Health Programme, Ministry of Health, Banjul, The Gambia.
Mabula KasubiMuhimbili Medical Center, Dar es Salaam, Tanzania.
Amir B KelloWorld Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.ORCID http://orcid.org/0000-0003-0150-9186
Robert KoUniversity of Papua New Guinea, Port Moresby, Waigani, Papua New Guinea.
Patrick J LammieNeglected Tropical Diseases Support Center, Task Force for Global Health, Atlanta, GA, USA.
Andres G LescanoSchool of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID http://orcid.org/0000-0001-9779-633X
Ramatou MalikiThe Carter Center, Niamey, Niger.
Michael Peter MasikaNational Eye Care Coordinator, Ministry of Health, Lilongwe, Malawi.
Stephanie J MigchelsenLondon School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0003-2049-9040
Beido NassirouThe Carter Center, Khartoum, Sudan.
John M NesemannF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9948-6498
Nishanth ParameswaranDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Willie PomatPNG Institute of Medical Research, Port Moresby, Waigani, Papua New Guinea.ORCID http://orcid.org/0000-0003-2640-9640
Kristen K RennekerInternational Trachoma Initiative, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8036-4776
Chrissy RobertsLondon School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0003-1064-5980
Prudence RymilMinistry of Health, Port Vila, Vanuatu.
Eshetu SataDepartment of Public Health Sciences, School of Medicine, University of California Davis CA, Davis, CA, USA.
Laura SenyonjoSightsavers, Haywards Heath, UK.
Fikre SeifeFederal Ministry of Health, Addis Ababa, Ethiopia.
Ansumana SillahThe National Eye Health Programme, Ministry of Health, Banjul, The Gambia.
Oliver SokanaSolomon Islands Ministry of Health and Medical Services, Honiara, Solomon Islands.
Ariktha SrivathsanF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3477-1757
Zerihun TadesseDepartment of Public Health Sciences, School of Medicine, University of California Davis CA, Davis, CA, USA.
Fasihah TaleoWorld Health Organization, Port Vila, Vanuatu.
Emma Michelle TaylorSightsavers, Haywards Heath, UK.
Rabebe TekeraoiMinistry of Health and Medical Services, South Tarawa, Kiribati.
Kwamy TogbeyMinistère de la Santé et de L'Hygiène Publique, Lomé, Togo.
Sheila K WestWilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Karana WickensDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-1437-4321
Timothy WilliamSubang Jaya Medical Centre, Subang Jaya, Malaysia.
Dionna M WittbergF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.
Dorothy Yeboah-ManuNoguchi Memorial Institute for Medical Research, Accra, University of Ghana, Ghana, Ghana.ORCID http://orcid.org/0000-0002-1663-6287
Mohammed YoubiDirection de l'Epidemiologie et de Lutte contre les Maladies, Rabat, Morocco.
Taye ZeruAmhara Public Health Institute, Bahir Dar, Ethiopia.
Jeremy D KeenanF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7118-1457
Thomas M LietmanF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8216-0240
Anthony W SolomonGlobal Neglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-7101-6649
Scott D NashThe Carter Center, Atlanta, GA, USA.
Diana L MartinDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Benjamin F ArnoldF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6105-7295
Funding
Peru Infectious Diseases Epidemiology Research Training ConsortiumD43TW007393 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI Andres G Lescano · 2005 to 2026
$5.9MSeroepidemiology of trachoma for the elimination endgameR01AI158884 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARNOLD, BENJAMIN F · 2021 to 2025
$2.0MModeling the dynamics of disease eliminationR35GM147702 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Seth Blumberg · 2022 to 2026
$2.0MIntegrating smartphone photography for trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoring - Diversity SupplementR33EY033690 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeremy David Keenan · 2023 to 2026
$1.0MIntegrating smartphone photography for trachoma, smartphone visual acuity assessment, and mobile autorefraction to enhance community-based public health monitoringR21EY033690 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID, LESCANO, ANDRES G · 2021 to 2022
$384kFIC NIH HHS D43 TW007393NEI NIH HHS R21 EY033690NEI NIH HHS R33 EY033690NIAID NIH HHS R01 AI158884NIGMS NIH HHS R35 GM147702World Health Organization 001
Abstract
Trachoma is targeted for global elimination as a public health problem by 2030. Measurement of IgG antibodies in children is being considered for surveillance and programmatic decision-making. There are currently no programmatic guidelines based on serology, which represents a generalizable problem in seroepidemiology and disease elimination. Here, we collate Chlamydia trachomatis Pgp3 and CT694 IgG measurements from 48 serosurveys across Africa, Latin America, and the Pacific Islands (41,168 children ages 1-5 years) and propose a novel approach to estimate the probability that population C. trachomatis transmission is below or above levels requiring ongoing programmatic action. We determine that trachoma programs could halt control measures with >90% certainty when seroconversion rates (SCRs) are ≤2.2 per 100 person-years. Conversely, SCRs ≥4.5 per 100 person-years correspond with >90% certainty that further control interventions are needed. More extreme SCR thresholds correspond with higher levels of confidence of elimination (lower SCR) or ongoing action needed (higher SCR). This study demonstrates a robust approach for using trachoma serosurveys to guide elimination program decisions.
Indexed as
Antibodies, BacterialChlamydia trachomatisDisease EradicationTrachomaAfricaAntigens, BacterialBacterial ProteinsChild, PreschoolFemaleHumansImmunoglobulin GInfantLatin AmericaMaleSeroepidemiologic StudiesAntibodies, BacterialAntigens, BacterialBacterial ProteinsImmunoglobulin Gpgp3 protein, Chlamydia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.